Proposal for the use of progression-free survival in unblinded randomized trials.
暂无分享,去创建一个
Boris Freidlin | Robert Gray | Edward L Korn | Sally Hunsberger | R. Gray | B. Freidlin | E. Korn | J. Zujewski | S. Hunsberger | S. Saxman | Jo Anne Zujewski | Scott Saxman
[1] A. Berger,et al. The effect of grouping on the power of the Mantel--Haenszel test for the comparison of survival rates , 1993 .
[2] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[3] K. Carroll,et al. Optimizing randomized phase II trials assessing tumor progression. , 2007, Contemporary clinical trials.
[4] M. Buyse. Cornerstones of a well-designed phase III trial , 2003 .
[5] M H Gail,et al. Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. , 1985, Controlled clinical trials.
[6] M. Buyse,et al. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[8] J. Cuzick. The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data , 1982 .
[9] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Kaptchuk,et al. Intentional Ignorance: A History of Blind Assessment and Placebo Controls in Medicine , 1998, Bulletin of the history of medicine.